During the past decade, Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 2 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" #1 sponsor was "Amgen" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "AIO-Studien-gGmbH" with 1 trials sponsored, "Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH" with 1 trials sponsored and "Technische Universität Dresden" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" #1 collaborator was "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" are "Myelodysplastic Syndromes" (2 trials), "Acute Myelogenous Leukemia" (1 trials), "Gastric and Gastroesophageal Junction Adenocarcinoma" (1 trials), "Gastrointestinal Cancers" (1 trials) and "Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive" (1 trials). Many other conditions were trialed in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" are "Drug" (6 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "13vPnC" (1 trials), "23vPS" (1 trials), "AMG 199" (1 trials), "AMG 910" (1 trials) and "Bevacizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Hamburg-Eppendorf /Onkologisches Zentrum, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".